Cytochroma’s product pipeline
includes the following candidates:
CTA018
Injection is a novel vitamin
D analog with a dual mechanism of action that combines
vitamin D hormone functions with CYP24 enzyme inhibition.
CTA018 Injection is under development for the treatment
of moderate to severe SHPT in Stage 5 CKD patients. The
product is expected to provide superior control of serum
parathyroid hormone (PTH) without having an adverse impact
on serum levels of calcium and phosphorus.
CTAP201
Injection is a vitamin D hormone
that is under development for the treatment of SHPT in
Stage 5 CKD patients. CTAP201 Injection will provide
nephrologists with a new alternative to safely and effectively
treat mild to moderate SHPT in dialysis patients.
CTAP101
Capsules is a first in class product under development
for the treatment of vitamin D insufficiency in Stage
3 and 4 CKD patients.
Other Product Candidates
Phosphate
Management Products in
early-stage development at Cytochroma target the treatment
of hyperphosphatemia in order to improve the control of
SHPT in CKD patients.